IB DCE calculates parameters for solid tumor perfusion and permeability analysis. IB DCE includes the Tofts, Extended Tofts, and Patlak models. IB DCE can be used to monitor tumor response to antiangiogenic and vascular disrupting agents, radiotherapy, and chemotherapy.
Product specifications Information source: Vendor
Last updated: July 31, 2020
General
Product name IB DCE
Company Imaging Biometrics
Subspeciality whole body application
Modality MR
Disease targeted tumors
Key-features Automated generation of perfusion parameter maps and Vascular Input Function, anatomical image registration, report generation
Suggested use
Data characteristics
Population
Input Dynamically acquired DCE datasets
Input format DICOM
Output Quantitative output of multi-parameter DCE maps
Output format DICOM
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Hybrid solution
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 10 - 60 seconds
Certification
CE Certified, Class I
FDA 510(k) cleared, Class II
Market presence
On market since 01-2013
Distribution channels Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, aycan Medical Systems, Pixmeo
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription
Based on Number of users, Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers